Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
“The cytotoxic effect is likely a result of inhibition of replication by cisplatin-DNA adducts and induction of apoptosis (Siddik, 2003).”
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
“An increase in cytosolic drug inactivation and a reduction in drug uptake are other possibilities [277,278].”
BackgroundDirect Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
“The cytotoxic lesions caused by platinating agents are known as platinum-DNA adducts, which primarily form intrastrand cross-links that activate the apoptotic pathway, resulting in cell death (Siddik, 2003).”
BackgroundDNA Mismatch Repair: Functions and Mechanisms
Iyer, R. R., Pluciennik, A., Burdett, V., & Modrich, P. L. (2006) · Chemical Reviews · doi:10.1021/cr0404794 · Cited by 905
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
“as well as in the machinery that de facto executes cell death.(12,48,154) Malignant cells are (i) intrinsically more resistant to adverse microenvironmental and intracellular cues than their non-transformed counterparts(155,156) and (ii) highly prone to acquire additional genetic and epigenetic alterations.”
BackgroundMetal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Pathophysiology of Cisplatin-Induced Acute Kidney Injury
Ozkok, A., & Edelstein, C. L. (2014) · BioMed Research International · doi:10.1155/2014/967826 · Cited by 703
“Pathophysiological pathways implicated in cisplatin-induced AKI and their in vivo therapeutic models and molecules are presented in Table 2.”
BackgroundDomingues, B., Lopes, J., Soares, P., & Populo, H. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s134842 · Cited by 701
“114 The most common BCT approach uses as chemotherapy a combination of dacarbazine, cisplatin (an antitumoral agent that induces DNA damage and apoptotic signals 115 ), and vinblastine (a microtubule targeting agent 116 ), with IL-2 and IFN α -2b as immunotherapy.”
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Engineering nanomedicine for glutathione depletion-augmented cancer therapy
Xiong, Y., Xiao, C., Li, Z., & Yang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00718h · Cited by 692
Ovarian damage from chemotherapy and current approaches to its protection
Spears, N., Lopes, F., Stefansdottir, A., Rossi, V, De Felici, M., Anderson, R. A., & Klinger, F. G. (2019) · Human Reproduction Update · doi:10.1093/humupd/dmz027 · Cited by 657
“The CISinduced DNA adducts are recognised by damage recognition proteins which transduce the DNA damage signal downstream and modulate several signal transduction pathways, such as Akt, c-ABL, ATR and MAPK/JNK/ERK (Siddik, 2003; Wang and Lippard, 2005).”
BackgroundRay, S., Mohan, R., Singh, J. K., Samantaray, M. K., Shaikh, M. M., Panda, D., & Ghosh, P. (2007) · Journal of the American Chemical Society · doi:10.1021/ja075889z · Cited by 656
Mechanisms of resistance to cisplatin and carboplatin
Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
Allocati, N., Masulli, M., Di Ilio, C., & Federici, L. (2018) · Oncogenesis · doi:10.1038/s41389-017-0025-3 · Cited by 625
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
DNA-Damaging Agents in Cancer Chemotherapy: Serendipity and Chemical Biology
Cheung-Ong, K., Giaever, G., & Nislow, C. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.007 · Cited by 591
Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury
Maekawa, H., Inoue, T., Ouchi, H., Jao, T.-M., Inoue, R., Nishi, H., Fujii, R., Ishidate, F., Tanaka, T., Tanaka, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.050 · Cited by 586
Magnetic nanoparticle-based therapeutic agents for thermo-chemotherapy treatment of cancer
Hervault, A., & Thanh, N. T. K. (2014) · Nanoscale · doi:10.1039/c4nr03482a · Cited by 585
Combination of Ru(ii) complexes and light: new frontiers in cancer therapy
Mari, C., Pierroz, V., Ferrari, S., & Gasser, G. (2015) · Chemical Science · doi:10.1039/c4sc03759f · Cited by 570
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Boutros, T., Chevet, E., & Metrakos, P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00106 · Cited by 545
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Huang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0969-3 · Cited by 476
Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment
Lenneman, C. G., & Sawyer, D. B. (2016) · Circulation Research · doi:10.1161/circresaha.115.303633 · Cited by 469
Subtype and pathway specific responses to anticancer compounds in breast cancer
Heiser, L. M., Sadanandam, A., Kuo, W.-L., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 475
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
“In cases of impaired repair or excessive damage, the cells undergo apoptosis (3).”
BackgroundAdvances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Porous Hollow Fe3O4 Nanoparticles for Targeted Delivery and Controlled Release of Cisplatin
Cheng, K., Peng, S., Xu, C., & Sun, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja903300f · Cited by 438
Chemophototherapy: An Emerging Treatment Option for Solid Tumors
Luo, D., Carter, K. A., Miranda, D., & Lovell, J. F. (2017) · Advanced Science · doi:10.1002/advs.201600106 · Cited by 436
Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?
Carozzi, V. A., Canta, A., & Chiorazzi, A. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.014 · Cited by 431
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433
Elloul, S., Bukholt Elstrand, M., Nesland, J. M., Tropé, C. G., Kvalheim, G., Goldberg, I., Reich, R., & Davidson, B. (2005) · Cancer · doi:10.1002/cncr.20946 · Cited by 429
Knoll, J. D., & Turro, C. (2015) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.05.018 · Cited by 423
Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., & Rigobello, M. P. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.12.021 · Cited by 415
How do chemotherapeutic agents damage the ovary?
Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H., & Spears, N. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms022 · Cited by 409
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
Molecular mechanisms of cisplatin resistance in cervical cancer
Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s106412 · Cited by 407
“4 Epigenetic drugs such as 5-azacytidine have been shown to block aberrant DNA methylation and thus reverse CPR. 64 Combination of cisplatin and 5-aza-2 ′ -deoxycytidine, a demethylating agent, significantly enhances the sensitivity to cisplatin in ME180 parent cells and the CPR subclones, and the removal of 5-aza-2 ′…”
BackgroundInfluentialContribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.139 · Cited by 399
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382
Mismatch repair and DNA damage signalling
Stojic, L., Brun, R., & Jiricny, J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.06.006 · Cited by 396
Dumbbell-like Au−Fe3O4 Nanoparticles for Target-Specific Platin Delivery
Xu, C., Wang, B., & Sun, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900790v · Cited by 390
Romani, A. M. P. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 383
Metal-NHC complexes: a survey of anti-cancer properties
Teyssot, M.-L., Jarrousse, A.-S., Manin, M., Chevry, A., Roche, S., Norre, F., Beaudoin, C., Morel, L., Boyer, D., Mahiou, R., et al. (2009) · Dalton Transactions · doi:10.1039/b906308k · Cited by 384
Brock, P. R., Knight, K. R., Freyer, D. R., Campbell, K. C. M., Steyger, P. S., Blakley, B. W., Rassekh, S. R., Chang, K. W., Fligor, B. J., Rajput, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1110 · Cited by 380
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Chou, A. J., & Gorlick, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1075 · Cited by 377
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin
Aldossary, S. A. (2019) · Biomedical and Pharmacology Journal · doi:10.13005/bpj/1608 · Cited by 366
Saito, T., Ichimura, Y., Taguchi, K., Suzuki, T., Mizushima, T., Takagi, K., Hirose, Y., Nagahashi, M., Iso, T., Fukutomi, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12030 · Cited by 362
Cisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361
Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Steg, A. D., Bevis, K. S., Katre, A. A., Ziebarth, A., Dobbin, Z. C., Alvarez, R. D., Zhang, K., Conner, M., & Landen, C. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2188 · Cited by 359
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Hdac3 is essential for the maintenance of chromatin structure and genome stability
Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.022 · Cited by 353
Platinum Drug Distribution in Cancer Cells and Tumors
Klein, A. V., & Hambley, T. W. (2009) · Chemical Reviews · doi:10.1021/cr9001066 · Cited by 351
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341
“Carboplatin generates DNA damage, which in turns activates the p53 pathway driving cell death, provided that p53 is functional (Siddik, 2003).”
BackgroundAdvances in cobalt complexes as anticancer agents
Munteanu, C. R., & Suntharalingam, K. (2015) · Dalton Transactions · doi:10.1039/c5dt02101d · Cited by 330
Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I., & Kovalchuk, O. (2010) · International Journal of Cancer · doi:10.1002/ijc.25191 · Cited by 334
Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, F., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F. O., Ferrandina, G., et al. (2005) · PubMed · Cited by 323
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Gyurászová, M., Gurecká, R., Bábíčková, J., & Tóthová, Ľ. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5478708 · Cited by 322
“Cisplatin invokes increased ROS production after being activated into a highly reactive form, reacts with thiol-containing molecules, such as glutathione (GSH), and depletes them [52, 53].”
ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707568200 · Cited by 309
Yolk/shell nanoparticles: classifications, synthesis, properties, and applications
Purbia, R., & Paria, S. (2015) · Nanoscale · doi:10.1039/c5nr04729c · Cited by 307
A potent cytotoxic photoactivated platinum complex
Mackay, F. S., Woods, J. A., Heringová, P., Kašpárková, J., Pizarro, A. M., Moggach, S. A., Parsons, S., Brabec, V., & Sadler, P. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707742105 · Cited by 303
Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, F., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F. O., Ferrandina, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.298.11.1 · Cited by 303
The Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Pierroz, V., Joshi, T., Leonidova, A., Mari, C., Schur, J., Ott, I., Spiccia, L., Ferrari, S., & Gasser, G. (2012) · Journal of the American Chemical Society · doi:10.1021/ja307288s · Cited by 296
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90545.2008 · Cited by 283
Lilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
“This is in line with the finding that cisplatin resistance is most often a result of altered DNA repair mechanisms and not cellular depletion of the drug ([316] and see following section).”
BackgroundThe roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
Tamada, M., Nagano, O., Tateyama, S., Ohmura, M., Yae, T., Ishimoto, T., Sugihara, E., Onishi, N., Yamamoto, T., Yanagawa, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3024 · Cited by 275
He, C., Liu, D., & Lin, W. (2015) · ACS Nano · doi:10.1021/nn506963h · Cited by 274
“Cisplatin causes cytotoxicity mainly by inducing apoptosis while PDT causes cytotoxicity via both apoptosis and necrosis pathways.(52,53) By combining chemotherapy and PDT modalities into a single nanoparticle, NCP@pyrolipid can elicit both apoptosis and necrosis efficiently upon irradiation.”
BackgroundInduction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
He, G., Siddik, Z. H., Huang, Z., Wang, R., Koomen, J., Kobayashi, R., Khokhar, A. R., & Kuang, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208474 · Cited by 264
Self-citationYang, Y., Li, H., Hou, S., Hu, B., Liu, J., & Wang, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065309 · Cited by 263
Brozovic, A., Ambriović-Ristov, A., & Osmak, M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003601836 · Cited by 261
Tseng, C.-L., Su, W.-Y., Yen, K.-C., Yang, K.-C., & Lin, F.-H. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.010 · Cited by 260
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Song, I.-S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., & Kuo, M. T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1543.3.12 · Cited by 259
Self-citationMetallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis
Liang, X.-J., Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P. C., Zhao, Y., Gao, X., Sun, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909707107 · Cited by 256
Mammalian metallothioneins: properties and functions
Babula, P., Masarik, M., Adam, V., Eckschlager, T., Stiborova, M., Trnkova, L., Skutkova, H., Provaznik, I., Hubalek, J., & Kizek, R. (2012) · Metallomics · doi:10.1039/c2mt20081c · Cited by 255
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
Safaei, R., & Howell, S. B. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.007 · Cited by 254
Autophagy Guards Against Cisplatin-Induced Acute Kidney Injury
Takahashi, A., Kimura, T., Takabatake, Y., Namba, T., Kaimori, J., Kitamura, H., Matsui, I., Niimura, F., Matsusaka, T., Fujita, N., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.001 · Cited by 253
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity
Sánchez-González, P. D., López-Hernández, F. J., López-Novoa, J. M., & Morales, A. I. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2011.602662 · Cited by 250
Chu, I., Blackwell, K., Chen, S., & Slingerland, J. (2005) · Cancer Research · doi:10.1158/0008-5472.18.65.1 · Cited by 251
Loret, N., Denys, H., Tummers, P., & Berx, G. (2019) · Cancers · doi:10.3390/cancers11060838 · Cited by 247
“Platinum agents such as cisplatin and carboplatin (a less nephrotoxic and neurotoxic cisplatin derivative [75]) form DNA cross-links and platinum adducts between DNA and proteins, which causes DNA damage and subsequent cell death [76,77].”
BackgroundCurcumin Combination Chemotherapy: The Implication and Efficacy in Cancer
Tan, B. L., & Norhaizan, M. E. (2019) · Molecules · doi:10.3390/molecules24142527 · Cited by 244
“Despite this crosslink can induce apoptosis and inhibit cell prolifera ion [100], the efficacy of cisplatin is limited by the development of cell re istance.”
BackgroundMechanisms of hair cell death and protection
Cheng, A. G., Cunningham, L. L., & Rubel, E. W. (2005) · Current Opinion in Otolaryngology & Head and Neck Surgery · doi:10.1097/01.moo.0000186799.45377.63 · Cited by 243
Resistance against novel anticancer metal compounds: Differences and similarities
Heffeter, P., Jungwirth, U., Jakupec, M., Hartinger, C., Galanski, M. S., Elbling, L., Micksche, M., Keppler, B., & Berger, W. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.02.002 · Cited by 242
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.